

B AC
Sub 127
15. A method as set forth^{forth} in claim 14, wherein said at least one plasma protein recovered is selected from the group consisting of the factors of coagulation and fibrinolysis, immunoglobulins, glycoproteins and albumin.

Sub. B5
16. A method as set forth in claim 14, wherein said exchanging of said citrate and optionally of said citrate-bound metals is effected by a salt of an organic carboxylic acid having 2 to 20 carbon atoms.

17. A method as set forth in claim 14, wherein said exchanging of said citrate and optionally of said citrate-bound metals is effected by at least one substance selected from the group consisting of (a) caprylate and (a) tartrate.

Decanoic
C₁₀-mono
18. A method as set forth in claim 14, wherein said exchanging of said citrate and optionally of said citrate-bound metals is effected by an organic mono- or dicarboxylic acid having 2 to 4 carbon atoms. Acetate, tartrate
CCCCCO₄

19. A method as set forth in claim 14, wherein said plasma-protein-containing medicament prepared is substantially free from aluminum.

20. A method as set forth in claim 14, wherein said exchanging of said citrate and optionally of said citrate-bound metals is effected during one of a diafiltration, ultrafiltration, gel permeation chromatography and a chromatographic separation method, enabling a separation of said at least one protein from salts.
what

Sub. B6
21. A method as set forth in claim 14, further comprising subjecting said plasma-protein-containing solution to at least one of a purification and a concentration before said exchanging of said citrate and optionally of said citrate-bound metals.

Q1 X 22. A method as set forth in claim 14, further comprising subjecting said plasma-protein-containing solution to a treatment for virus inactivation of any viruses possibly present.

Sub. B6 X 23. A method as set forth in claim 22, wherein said treatment for virus inactivation is effected before said exchanging of said citrate and optionally of said citrate-bound metals. *ROHE 0° inact. virus production of Colyphactis*

X 24. A method as set forth in claim 22, wherein said treatment for virus inactivation is effected after said exchanging of said citrate and optionally of said citrate-bound metals.

X 25. A method as set forth in claim 22, wherein said treatment for virus inactivation is effected before and after said exchanging of said citrate and optionally of said citrate-bound metals.

Sub. B7 X 26. A method as set forth in claim 22, wherein said treatment for virus inactivation is a heat-treatment.

Sub. B7 X 27. A method as set forth in claim 22, wherein said treatment for virus inactivation is effected immediately after said recovering of at least one plasma protein, in the presence of the mono- or dicarboxylate.

28. A method as set forth in claim 14, wherein finishing of said medicament is effected exclusively with citrate-free components.

X 29. A method as set forth in claim 14, wherein said exchanging of said citrate and optionally of said citrate-bound metals is effected in the presence of sodium chloride.

sub D8
30. A method as set forth in claim 29, wherein said sodium chloride is at least 4% by weight sodium chloride solution.

Sub. B8
31. A plasma-protein-containing medicament obtainable by a method of preparing said plasma-protein-containing medicament from one of citrated plasma and a citrate-containing plasma fraction, said medicament being substantially free from undesired metals and said medicament neither taking up any metals when stored in metal-containing containers, and said method comprising

- exchanging citrate and optionally citrate-bound metals in a plasma-protein-containing solution for one of a water-soluble mono- or dicarboxylate or for an organic mono- or dicarboxylic acid under non-precipitating conditions,
- recovering at least one plasma protein, and
- finishing said medicament,

said medicament having a content of undesired metals of less than 100 $\mu\text{g/l}$.

32. A plasma-protein-containing medicament as set forth in claim 31, wherein said undesired metal is aluminum.

sub D107
33. A plasma-protein-containing medicament as set forth in claim 31, wherein said content of undesired metals is less than 10 $\mu\text{g/l}$.

Sub. B9
34. A plasma-protein-containing medicament as set forth in claim 31, wherein said content of undesired metals is less than 200 $\mu\text{g/l}$.

200 $\mu\text{g/l}$